| answer text |
<p>The Department is proud to invest £1.3 billion per year in health research through
the National Institute for Health and Care Research (NIHR). NIHR research expenditure
for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than
any other disease group.</p><p> </p><p>The Government, through the NIHR, is committed
to improving research into the cancers with the poorest survival rates, such as acute
myeloid leukaemia, by funding high quality, timely research that leads to improved
outcomes for patients and the public, and makes the health and social care system
more efficient, effective, and safe. Research evidence is vital for improving treatments
and outcomes for people, including those with pancreatic cancer, and other less survivable
cancers. The following table shows NIHR research spend on diagnosis, treatment, and
diagnosis and treatment of blood cancers, which includes leukaemia, since 2018:<br></p><table><tbody><tr><td><p>Number
of projects</p></td><td><p>Total awards value</p></td></tr><tr><td><p>Blood cancer
diagnosis</p></td><td><p>11</p></td><td><p>£11,900,000</p></td></tr><tr><td><p>Blood
cancer treatment</p></td><td><p>14</p></td><td><p>£14,700,000</p></td></tr><tr><td><p>Blood
cancer diagnosis and treatment</p></td><td><p>4</p></td><td><p>£7,700,000</p></td></tr></tbody></table><p><br>
In 2023, the Government awarded £2 million to new interdisciplinary research teams
tackling hard to treat cancers, via the Medical Research Council’s two-day cancer
sandpit strategic funding opportunity, focused on technological innovation for understanding
cancers with the poorest survival rates.</p><p><br> The NIHR continues to encourage
and welcome applications for research into any aspect of human health, including acute
myeloid leukaemia. All applications are assessed for funding by peer review committees.
The level of research spend in a particular area is driven by factors including the
quality of the proposals, and their scientific potential. All applications for research
into pancreatic cancer and other less survivable cancers, made through open competition,
have been funded.</p>
|
|
